Found 11 results
Author Keyword Title Type [ Year(Desc)]
Filters: Author is Muchiri, Ruth N and First Letter Of Keyword is C  [Clear All Filters]
2022
Muchiri RN, Kibitel J, Redick MA, van Breemen RB.  2022.  Advances in Magnetic Microbead Affinity Selection Screening: Discovery of Natural Ligands to the SARS-CoV-2 Spike Protein.. J Am Soc Mass Spectrom. 33(1):181-188.
Muchiri RN, Kibitel J, Redick MA, van Breemen RB.  2022.  Advances in Magnetic Microbead Affinity Selection Screening: Discovery of Natural Ligands to the SARS-CoV-2 Spike Protein.. J Am Soc Mass Spectrom. 33(1):181-188.
Muchiri RN, Kibitel J, Redick MA, van Breemen RB.  2022.  Advances in Magnetic Microbead Affinity Selection Screening: Discovery of Natural Ligands to the SARS-CoV-2 Spike Protein.. J Am Soc Mass Spectrom. 33(1):181-188.
van Breemen RB, Muchiri RN, Bates TA, Weinstein JB, Leier HC, Farley S, Tafesse FG.  2022.  Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants.. J Nat Prod. 85(1):176-184.
van Breemen RB, Muchiri RN, Bates TA, Weinstein JB, Leier HC, Farley S, Tafesse FG.  2022.  Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants.. J Nat Prod. 85(1):176-184.
van Breemen RB, Muchiri RN, Bates TA, Weinstein JB, Leier HC, Farley S, Tafesse FG.  2022.  Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants.. J Nat Prod. 85(1):176-184.
van Breemen RB, Muchiri RN, Bates TA, Weinstein JB, Leier HC, Farley S, Tafesse FG.  2022.  Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants.. J Nat Prod. 85(1):176-184.
Elkhadragy L, Khabbaz RC, Muchiri RN, Totura WM, Samuelson JP, Whiteley HE, van Breemen RB, R Lokken P, Gaba RC.  2022.  Pharmacokinetics and Early Tumor Response to Conventional Transarterial Chemoembolization with Sorafenib and Doxorubicin in a VX2 Rabbit Tumor Model.. J Vasc Interv Radiol. 33(10):1213-1221.e5.
Elkhadragy L, Khabbaz RC, Muchiri RN, Totura WM, Samuelson JP, Whiteley HE, van Breemen RB, R Lokken P, Gaba RC.  2022.  Pharmacokinetics and Early Tumor Response to Conventional Transarterial Chemoembolization with Sorafenib and Doxorubicin in a VX2 Rabbit Tumor Model.. J Vasc Interv Radiol. 33(10):1213-1221.e5.